has decided to embark on the path of fine-tuning and developing rhNGF in its formulation for clinical use, at its own biotech facility in L’Aquila. and in Naples, where there are the laboratories of Drug Discovery and Technology Formulation, within a long-term collaboration with CNR. Italian excellence: the Dompé Hub in L’Aquila. Dompé has concentrated its manufacturing and research and development activities at its L’Aquila hub.

Author: Jular Nikotaur
Country: Guinea-Bissau
Language: English (Spanish)
Genre: Marketing
Published (Last): 20 May 2006
Pages: 299
PDF File Size: 9.15 Mb
ePub File Size: 4.61 Mb
ISBN: 190-2-45415-975-1
Downloads: 6591
Price: Free* [*Free Regsitration Required]
Uploader: Fezilkree

Two lines for sachets, three lines for sticks, two lines for liquids for traditional products. Do you want to be redirected to the mobile version?

The site covers an area ofsquare metres. From this point the pharmaceutical product passes to primary packaging in clean rooms to be inserted into glass or plastic containers to which the eventual accessories, such as droppers or spray pumps, are added automatically.

Primary packaging — in a controlled air environment — in which the pharmaceutical product is inserted into the individual stick, packet or container.

The fruit of its own research, fompe drugs are capable of acting on the inhibition of interleukin-8 IL-8a molecule responsible for both the pathogenesis of type 1 diabetes and for the inflammatory reaction immediately following the transplantation of pancreatic islets, which limits the efficacy of this therapeutic approach, which is targeted to a group of patients with advanced-stage type-1 diabetes.

We suggest formulatio to update it for free by following one of the these links, choosing the browser you prefer: Click here to read more. In the downstream process the proNGF is first checked for its correct three-dimensional structure folding phase and then purified.

The entire upstream process is carried out in controlled environments that guarantee sterility and bacterial containment. You are going to leave this site.

In the turnover was million is focused both on the development of pharmaceuticals for therapeutic needs as yet unfulfilled, in the areas of ophthalmology, oncology, diabetes and organ transplant, as well as in the creation of innovative industrialisation processes of these.

In humans, NGF is naturally produced as pre-pro-peptide, secreted into the endoplasmic reticulum and dpmpe by furin protease. With the production of the inclusion bodies the upstream phase is concluded.


L’Aquila hub

You are going to leave this site. Currently being tested in Phase II clinical trials, the drug is designed to counteract in an innovative way the inflammatory reactions that characterise the early stage of type 1 diabetes.

The current annual production capacity is 50 million packs. Cenegermin is a human beta-nerve growth factor beta-ngf – – peptide non-covalent dimer produced in escherichia coli.

Blog Stats 2, hits. The most common adverse reactions in patients taking Oxervate are eye pain, ocular hyperemia enlarged blood vessels in the white of the eyeseye inflammation and increased lacrimation watery eyes. This site uses third party cookies. Clinical studies are therefore developed in cooperation with the above counterparts to ensure the highest level of safety to their participants, operating in full compliance with the scientific and ethical standards that govern clinical research and sharing the results of the research conducted with the scientific community, regulatory authorities and institutions.

In the second study, patients were randomized into two groups. Therefore these two amino acid changes forrmulation no influence on the final active ingredient rhNGFwhich is identical to the naturally secreted human formulatiion.

NGF was the first neurotrophic factor to be identified and purified and over the last fifty years, its role in neuronal development and its biological activity on neural tissue has been of great interest to science.

The aim is to convey all the metabolic energy of the bacterium with a solely reproductive aim.

Our research

formulatio The activity includes every stage of development, from refinement of the experimental design for creating the drug, to the identification of creative, innovative and flexible solutions that could lead to industrial production.

Accessing the website you have selected you will be subject formulagion the terms of use of this last. Flavio Mantelli, born in Rome inis the author of 40 international scientific publications and of numerous chapters in volumes about ophthalmology.

In this first phase the gene inserted in the bacterium for the production of the protein is rendered silent. The molecule is at an advanced stage of clinical development phase 3 in the field of therapeutic solutions to treat type 1 diabetes type as a way to improve the efficacy of pancreatic islet transplantation, whether autologous or allogeneic i.

This site uses third party cookies. At this point we move on to the second phase of packaging in boxes, wrapping and pallets. Sorry, your blog cannot share posts by email. The packaging is divided into forulation phases.


In the five successive hours the bacterial cells convey all their energy towards the production of the protein of interest, and in the end do not even have the energy to guarantee their survival. Biotechnological production comprises one upstream phase the production of the active principle from biological material and one downstream phase purification.

The safety of ladarixin in the specific clinical setting will be also evaluated. One group received Oxervate, a second group received an eye drop with a different concentration of cenegermin, and the third group received an eye drop without cenegermin. Reparixin oral tablets are being tested as a CSC targeting agent in patients with metastatic non- human epidermal growth factor receptor HER2 -amplified BC.

This site uses third party cookies. His friends call him Open superstar worlddrugtracker. By continuing to use this web site, you are consenting to the use of cookies. Reparixin is the first low molecular weight blocker of CXCL8 biological activity in clinical development. You are going to leave this site.

In his new role, Flavio Mantelli will also be responsible for managing the current and soon to be launched clinical trials on ophthalmology. The release technologies studied in this field are also applied to the treatment of dermatological pathologies the ongoing projects concern the controlled release of proteins for the treatment of wounds and the protection of topical formulations containing active ingredients that, following exposure to sunlight, generate toxic species.

For information, including how to block the cookies, click here.

Our research | Dompé

For information, including how to block the cookies, click here. Several laboratories are up and running at CDMO, for analytical development and formulatikn control, making it possible to conduct the most in-depth analyses in the biotechnology field. This unit also promotes networking for the development of highly-valued design platform partnerships.